Berberine ameliorates intestinal mucosal barrier dysfunction in nonalcoholic fatty liver disease (NAFLD) rats

被引:10
|
作者
Wang, Yuzhen [1 ]
Cui, Suxian [2 ]
Zheng, Jimin [1 ]
Li, Yueqin [1 ]
Li, Pingping [1 ]
Hou, Hongtao [1 ]
机构
[1] Hebei Gen Hosp, Dept Gastroenterol, Shijiazhuang 050051, Hebei, Peoples R China
[2] Hebei Med Univ, Dept Gastroenterol, Shijiazhuang 050017, Hebei, Peoples R China
关键词
Nonalcoholic fatty liver disease; Berberine; Intestinal mucosal barrier; ENDOTOXEMIA; DIET; NOD1;
D O I
10.1016/j.jksus.2020.03.019
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objective: To study the protective role of berberine (BBR) against nonalcoholic fatty liver disease (NAFLD) on intestinal barrier via investigating its effect on intestinal permeability and intestinal innate immune system in a rat model. Method: Sprague-Dawley rats were randomly divided into three groups: control rats (group N), high-fat diet (HFD) model rats (group M) and BBR-treated rats (group B). Rats in group M and group B were fed with HFD for 12 weeks to induce NAFLD. Rats in group B were then received 4 weeks of BBR administration with continuous HFD feeding. Samples were collected at 16th week. Results: HFD feeding increased the body weight of rats and caused liver steatosis as indicated by hematoxylin & eosin (H&E) staining. Analysis of serum parameters showed that alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol (TC), triglyceride (TG), endotoxin, interleukin-1 beta (IL-1 beta), interleukin-18 (IL-18), and tumor necrosis factor-alpha (TNF-alpha) were significantly higher in group M as compared group N. These results confirmed the successful establishment of NAFLD in rats. With 4 weeks of BBR administration, body weight of group B decreased significantly as compared with group M. Serum levels of ALT, AST, TC, TG, endotoxin, IL-1 beta, IL-18 and TNF-alpha reduced significantly and hepatocyte steatosis ameliorated. RT-PCR and Western blot analysis showed that BBR reduced the elevated mRNA and protein expressions of innate immune response elements NOD1, NOD2 and NLRP3 that were caused by HFD. BBR also antagonized the effect of NAFLD on Caspase-1 and Claudin-4 protein expressions. Conclusions: BBR alleviates endotoxemia, reduces serum lipids, increases liver function, reduces systemic inflammation and diminishes liver inflammation and steatosis in NAFLD rats. The protective effect of BBR against NALFD is achieved through ameliorating intestinal mucosal barrier dysfunction partly by improving permeability of intestinal mucosa and modulating intestinal innate immune components. (C) 2020 The Authors. Published by Elsevier B.V. on behalf of King Saud University.
引用
收藏
页码:2534 / 2539
页数:6
相关论文
共 50 条
  • [1] Amelioration of Intestinal Barrier Dysfunction by Berberine in the Treatment of Nonalcoholic Fatty Liver Disease in Rats
    Li, Donghao
    Zheng, Jimin
    Hu, Yiting
    Hou, Hongtao
    Hao, Shurong
    Liu, Na
    Wang, Yuzhen
    PHARMACOGNOSY MAGAZINE, 2017, 13 (52) : 677 - 682
  • [2] Intestinal mucosal barrier dysfunction participates in the progress of nonalcoholic fatty liver disease
    Mao, Jing-Wei
    Tang, Hai-Ying
    Zhao, Ting
    Tan, Xiao-Yan
    Bi, Jian
    Wang, Bing-Yuan
    Wang, Ying-De
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (04): : 3648 - 3658
  • [3] Intestinal permeability in nonalcoholic fatty liver disease (NAFLD).
    Miele, L
    Valenza, V
    Mascianà, R
    Gabrieli, ML
    Perotti, G
    Cammarota, G
    Montalto, M
    Forgione, A
    Vero, V
    Gasbarrini, G
    Grieco, A
    HEPATOLOGY, 2004, 40 (04) : 585A - 585A
  • [4] Magnesium isoglycyrrhizinate attenuates nonalcoholic fatty liver disease by strengthening intestinal mucosal barrier
    Lai, Xueying
    Zhou, Hong
    Wan, Yu
    Kuang, Jiesi
    Yang, Yuhui
    Mai, Limei
    Chen, Yumei
    Liu, Bin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 128
  • [5] Chrysin ameliorates nonalcoholic fatty liver disease in rats
    Pai, Sarayu A.
    Munshi, Renuka P.
    Panchal, Falguni H.
    Gaur, Ila-Shruti
    Juvekar, Archana R.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2019, 392 (12) : 1617 - 1628
  • [6] Chrysin ameliorates nonalcoholic fatty liver disease in rats
    Sarayu A. Pai
    Renuka P. Munshi
    Falguni H. Panchal
    Ila-Shruti Gaur
    Archana R. Juvekar
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2019, 392 : 1617 - 1628
  • [7] Berberine Attenuates Intestinal Mucosal Barrier Dysfunction in Type 2 Diabetic Rats
    Gong, Jing
    Hu, Meilin
    Huang, Zhaoyi
    Fang, Ke
    Wang, Dingkun
    Chen, Qingjie
    Li, Jingbin
    Yang, Desen
    Zou, Xin
    Xu, Lijun
    Wang, Kaifu
    Dong, Hui
    Lu, Fuer
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [8] Nonalcoholic Fatty Liver disease (NAFLD)
    Zeuzem, S.
    Trautwein, C.
    GASTROENTEROLOGE, 2020, 15 (02): : 77 - 77
  • [9] Biomarkers of endothelial dysfunction in patients with nonalcoholic fatty liver disease (NAFLD)
    Montero-Vallejo, Rocio
    Gallego-Duran, Rocio
    Maya, Douglas
    Gato Zambrano, Sheila
    Garcia Fernandez, Vanessa
    Munoz Hernandez, Rocio
    Gil-Gomez, Antonio
    Alvarez-Ossorio, Angela Rojas
    Fernandez-Barrena, Maite G.
    Maria Herranz, Jose
    Hernandez-Gea, Virginia
    Camprecios, Genis
    Anton, Aina
    del Carmen Rico, Maria
    Martin-Bermudo, Franz
    Romero Gomez, Manuel
    Ampuero, Javier
    JOURNAL OF HEPATOLOGY, 2023, 78 : S770 - S772
  • [10] A Comprehensive Insight into the Effect of Berberine on Nonalcoholic Fatty Liver Disease (NAFLD): A Systematic Review
    Karimi, Arash
    Vajdi, Mahdi
    Sanaie, Sarvin
    Akhlaghi, Shiva
    Negari, Aida
    Dashti, Farzaneh
    Sefidmooye Azar, Pouria
    JOURNAL OF FOOD BIOCHEMISTRY, 2023, 2023